Lemaitre Vascular Inc (LMAT) · Oct 15, 2026 · Exec change
President retirement — Retires December 31, 2026; board term runs through 2029
LeMaitre Vascular announces its longtime president will retire in December while remaining a director, leaving the succession plan unresolved.
LeMaitre is a specialized vascular-device and human-tissue business built around products used in vascular surgery, with David Roberts serving as a long-tenured operating leader and board member.
This is a leadership transition, not a departure from the company. Roberts will retire as an employee and President on December 31, 2026, but intends to remain on the board through his current 2029 term. 〔0〕
The main unresolved issue is succession. The filing names no replacement or transition timetable, so the market learns that a change is coming but not who will run the operating business afterward. That makes the event partly reassuring—continuity at the board level remains—but operationally incomplete.
Roberts’s tenure makes this more meaningful than a routine executive reshuffle. He has been President since 2007 and joined the company in 1997, while the filing describes 29 years of executive service. 〔1〕
Bottom line: LeMaitre is losing a longtime day-to-day leader while retaining his institutional knowledge on the board. The immediate business impact is unclear until the company identifies his successor; the filing is therefore a meaningful but incomplete succession disclosure.
Naming David Roberts’s successor as President
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!